{"url_path":"/sec/mltx/8-k/2026-06-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-070362-index.html","accession_number":"0001213900-26-070362","cik":"0001821586","ticker":"MLTX","issuer_name":"MoonLake Immunotherapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-070362-index.html","primary_entity_key":"0001821586","primary_entity_name":"MoonLake Immunotherapeutics"},"word_count":316,"has_tables":true,"body_markdown":"false\n0001821586\n\n0001821586\n\n2026-06-21\n2026-06-21\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n****\n\n \n\n****\n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n** **\n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\n** **\n\n**PURSUANT TO SECTION 13 or 15(d) of the**\n\n**SECURITIES EXCHANGE ACT OF 1934**\n\n** Date of Report\n(Date of earliest event reported): June 21, 2026**\n\n** **\n\n \n\n \n\n**MOONLAKE IMMUNOTHERAPEUTICS**\n\n(Exact Name of Registrant as Specified in Its Charter)\n\n \n\n**Cayman Islands**\n \n**001-39630**\n \n**98-1711963**\n\n(State or Other Jurisdiction\n\nof Incorporation)\n\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n****\n\n \n\n**Dorfstrasse 29**\n\n**6300 Zug**\n\n**Switzerland**\n\n(Address of principal executive offices and Zip\nCode)\n\n \n\n**41 415108022**\n\n(Registrant’s Telephone Number, Including\nArea Code)\n\n \n\n**N/A**\n\n(Former Name\nor Former Address, if Changed Since Last Report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nClass A ordinary share, par value $0.0001 per share\n \nMLTX\n \nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}